Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax-Enhanced Reduced Intensity HLA-Mismatched Allogeneic Transplant for Ultra-High-Risk AML and MDS
NCT06337331Phase 2Withdrawn
- Sponsor
- Northside Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Northside Hospital. Planned start Aug 2024; status: withdrawn.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06337331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337331.